Live · Librarian-verified
GLP-1 Availability & Access (2026)
How patients actually access GLP-1 drugs in 2026 — from the new oral semaglutide pill to direct-to-patient cash-pay programs — as telehealth compounding routes narrow.
4
Points tracked
4
Points current
10m
Since last verification
0
Points expired
Point statusCurrent — confirmed within its check windowChanged — the underlying fact movedPending — re-check queuedExpired — past its window, treat as unverified
Inside a tracker
Access to GLP-1 drugs remains limited · 4 points| Tracked statement | Status | Source | Last confirmed |
|---|---|---|---|
| Oral semaglutide (Wegovy pill) — Available — Needle-free oral option.Needle-free oral option. | Current | — | Aug 16, 2026 |
| Direct-to-patient (LillyDirect) — Available — Zepbound self-pay | Current | — | Aug 16, 2026 |
| Direct-to-patient (NovoCare) — Available — Wegovy ~$349 cash-pay | Current | — | Aug 16, 2026 |
| Telehealth compounded access — Severely restricted after FDA crackdown | Current | — | Aug 20, 2026 |
Expired does not mean false — it means nobody has confirmed it recently enough for us to stand behind it. Nothing on this tracker is past its window right now.
How we keep this current
Our AI Librarian periodically re-checks each line against primary sources — FDA notices, manufacturer announcements, and clinical-trial registries — and re-stamps the "last verified" date above. Fast-moving regulatory facts can still change between checks; always confirm against the linked primary source before relying on any single line.